文献速递流行病学与生物统计临床试验与 GCP

全身性糖皮质激素与重症COVID-19患者死亡率的关系:一项Meta分析

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.
PubMed 文献 · JAMA · 2020-01-01

该前瞻性Meta分析汇总7项随机临床试验、1703例重症COVID-19患者数据,比较全身性糖皮质激素与常规治疗或安慰剂对28天全因死亡率的影响。固定效应模型显示糖皮质激素组死亡率显著降低(OR 0.66,95%CI 0.53-0.82;

要点

  • 重症COVID-19患者使用全身性糖皮质激素与28天全因死亡率降低相关。
  • 氢化可的松和甲泼尼龙亚组未显示显著获益。

核心结论

  • 在重症COVID-19患者中,与常规治疗或安慰剂相比,全身性糖皮质激素给药与较低的28天全因死亡率相关。

研究设计与样本

  • 前瞻性Meta分析汇总7项评估糖皮质激素疗效的随机临床试验,共纳入1703例重症COVID-19患者。
  • 试验于2020年2月26日至6月9日在12个国家开展,最终随访日期为2020年7月6日。
  • 678例随机接受全身性地塞米松、氢化可的松或甲泼尼龙,1025例随机接受常规治疗或安慰剂。
  • 主要分析为逆方差加权固定效应Meta分析,关联以比值比(OR)量化;另进行随机效应Meta分析和基于风险比的固定效应分析。

主要发现

  • 共1703例患者(中位年龄60岁,四分位距52-68岁;488例[29%]女性)纳入分析。

关键数值与推荐

  • 主要结局为随机化后28天全因死亡率;次要结局为研究者定义的严重不良事件。
  • 5项试验报告28天死亡率,1项报告21天死亡率,1项报告30天死亡率。
  • 7项试验中6项死亡结果偏倚风险评为「低」,1项因随机化方法评为「有一些担忧」。

临床怎么用

  • 对于需要呼吸支持的重症COVID-19住院患者,可考虑使用全身性糖皮质激素以降低28天全因死亡率。
  • 地塞米松在固定效应分析中显示显著死亡率获益,氢化可的松和甲泼尼龙未显示显著获益。

局限性

  • 各糖皮质激素亚组分析中氢化可的松和甲泼尼龙试验数量及样本量有限。
  • 1项试验因随机化方法存在「有一些担忧」的偏倚风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Effective therapies for patients with coronavirus disease 2019 (COVID-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support. OBJECTIVE: To estimate the association between administration of corticosteroids compared with usual care or placebo and 28-day all-cause mortality. DESIGN, SETTING, AND PARTICIPANTS: Prospective meta-analysis that pooled data from 7 randomized clinical trials that evaluated the efficacy of corticosteroids in 1703 critically ill patients with COVID-19. The trials were conducted in 12 countries from February 26, 2020, to June 9, 2020, and the date of final follow-up was July 6, 2020. Pooled data were aggregated from the individual trials, overall, and in predefined subgroups. Risk of bias was assessed using the Cochrane Risk of Bias Assessment Tool. Inconsistency among trial results was assessed using the I2 statistic. The primary analysis was an inverse variance-weighted fixed-effect meta-analysis of overall mortality, with the association between the intervention and mortality quantified using odds ratios (ORs). Random-effects meta-analyses also were conducted (with the Paule-Mandel estimate of heterogeneity and the Hartung-Knapp adjustment) and an inverse variance-weighted fixed-effect analysis using risk ratios. EXPOSURES: Patients had been randomized to receive systemic dexamethasone, hydrocortisone, or methylprednisolone (678 patients) or to receive usual care or placebo (1025 patients). MAIN OUTCOMES AND MEASURES: The primary outcome measure was all-cause mortality at 28 days after randomization. A secondary outcome was investigator-defined serious adverse events. RESULTS: A total of 1703 patients (median age, 60 years [interquartile range, 52-68 years]; 488 [29%] women) were included in the analysis. Risk of bias was assessed as "low" for 6 of the 7 mortality results and as "some concerns" in 1 trial because of the randomization method. Five trials reported mortality at 28 days, 1 trial at 21 days, and 1 trial at 30 days. There were 222 deaths among the 678 patients randomized to corticosteroids and 425 deaths among the 1025 patients randomized to usual care or placebo (summary OR, 0.66 [95% CI, 0.53-0.82]; P < .001 based on a fixed-effect meta-analysis). There was little inconsistency between the trial results (I2 = 15.6%; P = .31 for heterogeneity) and the summary OR was 0.70 (95% CI, 0.48-1.01; P = .053) based on the random-effects meta-analysis. The fixed-effect summary OR for the association with mortality was 0.64 (95% CI, 0.50-0.82; P < .001) for dexamethasone compared with usual care or placebo (3 trials, 1282 patients, and 527 deaths), the OR was 0.69 (95% CI, 0.43-1.12; P = .13) for hydrocortisone (3 trials, 374 patients, and 94 deaths), and the OR was 0.91 (95% CI, 0.29-2.87; P = .87) for methylprednisolone (1 trial, 47 patients, and 26 deaths). Among the 6 trials that reported serious adverse events, 64 events occurred among 354 patients randomized to corticosteroids and 80 events occurred among 342 patients randomized to usual care or placebo. CONCLUSIONS AND RELEVANCE: In this prospective meta-analysis of clinical trials of critically ill patients with COVID-19, administration of systemic corticosteroids, compared with usual care or placebo, was associated with lower 28-day all-cause mortality.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Sterne JAC, Murthy S, Diaz JV, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020. PMID: 32876694. doi:10.1001/jama.2020.17023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。